Nov Access Global Inc. XSNX
We take great care to ensure that the data presented and summarized in this overview for NovAccess Global Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in XSNX
Top Purchases
Top Sells
About XSNX
NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. The company specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. NovAccess Global Inc. was incorporated in 1997 and is headquartered in Chesterland, Ohio.
Insider Transactions at XSNX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2022
|
Dwain Morris Irvin Chief Executive Officer |
BUY
Other acquisition or disposition
|
Indirect |
600
+50.0%
|
-
|
|
Mar 14
2022
|
Daniel G. Martin > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
1,502,670
+50.0%
|
-
|
|
Mar 14
2022
|
Daniel G. Martin > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
25,000
-100.0%
|
-
|
|
Jan 20
2022
|
Neil J Laird Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
250,000
+49.02%
|
$0
$0.2 P/Share
|
|
Oct 03
2021
|
Neil J Laird Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Jan 19
2021
|
Larry Michael Yukich Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
-
|
|
Nov 23
2020
|
Dwain Morris Irvin Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,800,000
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders